Xu Yulian, Sun Xueli, Tong Yunguang
College of Life Sciences, China Jiliang University, 168 Xueyuan Street, Hangzhou, Zhejiang, China.
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Discov Oncol. 2024 May 16;15(1):170. doi: 10.1007/s12672-024-01011-2.
Interleukin-12 (IL-12) can be used as an immunomodulator in cancer immunotherapy. And it has demonstrated enormous potential in inhibiting tumor growth and improving the tumor microenvironment (TME) by several preclinical models. However, some disappointing results have showed in the early clinical trials when IL-12 used as a single agent for systemic cancer therapy. Combination therapy is an effective way to significantly fulfill the great potential of IL-12 as an immunomodulator. Here, we discuss the effects of IL-12 combined with traditional methods (chemotherapy, radiotherapy and surgery), targeted therapy or immunotherapy in the preclinical and clinical studies. Moreover, we summarized the potential mechanism underlying the anti-tumor effect of IL-12 in the combination strategies. And we also discussed the delivery methods and tumor-targeted modification of IL-12 and outlines future prospects for IL-12 as an immunomodulator.
白细胞介素-12（IL-12）可作为癌症免疫治疗中的一种免疫调节剂。通过多种临床前模型，它在抑制肿瘤生长和改善肿瘤微环境（TME）方面已显示出巨大潜力。然而，当IL-12作为单一药物用于全身性癌症治疗时，早期临床试验出现了一些令人失望的结果。联合治疗是充分发挥IL-12作为免疫调节剂巨大潜力的有效途径。在此，我们讨论了在临床前和临床研究中IL-12与传统方法（化疗、放疗和手术）、靶向治疗或免疫治疗联合使用的效果。此外，我们总结了IL-12在联合策略中抗肿瘤作用的潜在机制。我们还讨论了IL-12的递送方法和肿瘤靶向修饰，并概述了IL-12作为免疫调节剂的未来前景。
